Tue, Jul 29, 2014, 3:00 PM EDT - U.S. Markets close in 1 hr.

Recent

% | $
Click the to save as a favorite.

Deckers Outdoor Corp. Message Board

oilman_12345 6 posts  |  Last Activity: Apr 16, 2014 10:32 PM Member since: Jun 17, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    im8400

    by oilman_12345 Apr 16, 2014 11:11 AM
    oilman_12345 oilman_12345 Apr 16, 2014 10:32 PM Flag

    A Recent Disconnect:
    On March 24, 2014 only a few days prior to the announcement of the Idera P2 trial, Celgene (CELG) announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of adult patients with active "psoriatic arthritis." While I do believe that the approval of this "pill" is great news for Celgene, this is not and was not the intended goal that Idera was striving for in its IMO-8400 trial. According to my research, Idera has never intended to go into this already crowded space (but has stated in its webcasts and news releases that they could partner this out).
    Given these recent announcements, I do believe that investors sold on this news, which is an unwarranted response, hence the disconnect. Maybe investors aren't looking deep enough into the real translation of the data to see that we are actually are on the cusp of something very remarkable. The positive Top-Line data seems to be clearly overlooked, misunderstood and misrepresented by the individual investor. In simple terms, the current stock price is not representative of its real value. We are only seeing a piece of the iceberg floating above the water. I could be wrong, but I don't believe that I am and I will be anxiously waiting for more data from the "higher dose" cohorts to be announced later in Q2 of 2014 which could be a pivotal event.

  • Reply to

    im8400

    by oilman_12345 Apr 16, 2014 11:11 AM
    oilman_12345 oilman_12345 Apr 16, 2014 11:53 AM Flag

    This question that I pose is exactly why I believe that Idera Pharmaceuticals has amassed what I would call the elite team of biotech leaders and investment bankers over the past several quarters. What I am referring to is Idera's highly gifted management team, it's board, leadership, and two main investment firms; Pillar Invest Corp. and Baker Brothers Advisors.

  • oilman_12345 by oilman_12345 Apr 16, 2014 11:11 AM Flag

    Idera Pharmaceuticals - A Buying Opportunity Following The Fade by EXPstocktrader

    April 16, 2014

    If you have been following Idera Pharmaceuticals (IDRA), you know that they have been ramping up as one of the most cutting edge companies in the field of discovery and development of its TLR Antagonists, as well as synthetic DNA- and RNA- based drug candidates which I believe could radically change gene therapies in medicine today.

    Abstract #2570 As Presented at AACR in San Diego, CA on April 7, 2014

    In my review, the preclinical data is quite impressive and almost certainly provides a strong rationale for the phased studies being performed by Idera in ABC-DLBCL and Waldenstrom Macroglobulinemia. We are of course in the early stages, but what is most exciting about this poster is the proof of concept in its TLR Antagonists that are being used in its... In vitro Studies in MYD88 L265P - Positive ABC-DLBCL Cell Lines.

  • oilman_12345 by oilman_12345 Apr 14, 2014 1:38 PM Flag

    Hopefully everyone loaded up on the cheap shares!

  • Reply to

    Ibb greennnn

    by mike_khieu Apr 9, 2014 10:02 AM
    oilman_12345 oilman_12345 Apr 9, 2014 10:05 AM Flag

    last day to get in under 4!

  • oilman_12345 by oilman_12345 Apr 8, 2014 10:33 PM Flag

    It is at the same price as 12/13, however, the following positive data points have been released since:

    Julian Baker and Kevin Neu of BB join the board.
    Coverage issued by Cowen and set price target of 7.
    Had 40 million stock offering to have sufficient funds to run business for 2 more years.
    Lou Brenner named Chief Medical Officer from Radius Health
    Mark Goldberg joins board with experience from Synageva and Genzyme
    Idera also intends to initiate clinical development of IMO-8400 in patients with diffuse large B-cell lymphoma (DLBCL) harboring the MYD88 L265P mutation. The Company has recently submitted a protocol for a Phase 1/2 trial in this indication.
    In December 2013, Idera was cleared to open enrollment in its Phase 1/2 trial of IMO-8400 in patients with Waldenström’s macroglobulinemia, a form of non-Hodgkin lymphoma. The trial is designed to evaluate IMO-8400’s safety, tolerability and potential clinical activity in patients who have a history of relapse or failure to respond to one or more prior therapies. The Company anticipates that patient treatment in this trial will begin in the first half of 2014.
    Idera announced today its plans to initiate clinical development of its lead compound, IMO-8400, for the treatment of patients with polymyositis and dermatomyositis in the first half of 2014.
    Idera Pharmaceuticals announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis.

DECK
89.71-1.05(-1.16%)3:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.